To compare effect of Atibala Vati with Tab Regestrone in management of heavy menstrual bleeding.

Randomized controlled clinical study to evaluate the effect of Atibala Vati in comparison with Tab Regestrone in management of Asrigdara. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061877

Enrollment

Registered

2024-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Increased number of bleeding days that is more than 7 days 2. Quantitative increase in Menstrual blood that is more than 80 ml or more than 3 pads per day. 3. Decreased Intermenstrual period that is less than 21 days

Exclusion criteria

Exclusion criteria: 1. Traumatic bleeding 2. Post menopausal bleeding 3. Cervical uterine ovarian Neoplasm 4. Fibroid 5. Endometriosis. 6.Bleeding through Gravid uterus 7. cerical polyp and erosion 8. Coagulopathy

Design outcomes

Secondary

Measure	Time frame
objective criteria 1. USG ET before and after 2.Haemogram count before and afterTimepoint: 15 30 days	—

Primary

Measure	Time frame
Patient was diagnosed on the basis of signs and symptoms described in Ayurvedic texts and Modern approach that is subjective and objective criteria Subjective Criteria 1. Duration of bleeding in days 2. Quantity of blood lossTimepoint: 3 6 10 days	—

Countries

India

Contacts

Public ContactDrSanjay G Gavane

Tilak Ayurved Mahavidyalaya, Pune

dr.sanjaygavane@yahoo.co.in9822254700

Outcome results